Sen. Sanders Calls for Drastically Reduced Ozempic Pricing, Rips Novo Nordisk

Americans are being gouged by the “outrageously high price” of a popular diabetes drug, charged Sen. Bernie Sanders (I-Vt.) Wednesday in a scathing rebuke of Novo Nordisk.

Sanders, Chairman of the Senate Health, Education, Labor and Pensions (HELP) Committee, demanded the manufacturer of Ozempic (semaglutide) lower the price of the drug in the U.S., warning of the potential bankruptcy of “Medicare, the American people and our entire healthcare system.”

Sanders cited a study published Wednesday in JAMA Network Open stating that Ozempic could be manufactured for an estimated 89 cents to $4.73 per month — figures that include a profit margin — while Novo Nordisk charges $935.77 monthly for the injection in the U.S. before insurance.

Read Sen. Sanders’ news release here.

To read the whole story, click here to subscribe.

Related Topics